|
|
Exchange: |
Nasdaq National Market |
Security
Type: |
Common |
Shares
Out: |
44,930,000 |
Market
Cap: |
59.76(M) |
Last
Volume: |
13,996 |
Avg
Vol: |
310,930 |
52
Week Range: |
$1.28 - $2.6 |
|
Level
I Sector: |
Health Care |
Level
II Sector: |
Drugs |
Level
III Sector: |
Biotechnology |
|
Member Indexes:
|
Rankings:
|
Insider 3 Months : - |
Insider 6 Months : - |
Insider 3/6 Months : - |
|
Guru Rank Number : - |
Guru Rank Value : - |
Guru Occurances : - |
|
|
|
|
|
|
|
Company Profile MediciNova is a biopharmaceutical company. Co. is focusing its development activities on MN-166 (ibudilast) for neurological and other disorders such as progressive multiple sclerosis, amyotrophic lateral sclerosis, chemotherapy-induced peripheral neuropathy, degenerative cervical myelopathy, glioblastoma, substance dependence and addiction and prevention of acute respiratory distress syndrome, and MN-001 (tipelukast) for fibrotic diseases such as nonalcoholic steatohepatitis and idiopathic pulmonary fibrosis. Co.'s pipeline also includes MN-221 (bedoradrine) for the treatment of acute exacerbation of asthma and MN-029 (denibulin) for solid tumor cancers.
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
3m +/-:
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
Actions:
|
|
|
B |
Buy |
S |
Sell |
OE |
Option
Exercised |
A |
Acquired |
D |
Disposed |
AB |
Automatic
Buy |
AS |
Automatic
Sell |
IO |
Initial
Ownership |
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
|
|
Summary (Direct Transactions Only) |
3 Months |
6 Months |
12 Months |
24 Months |
Total Shares Bought |
0 |
0 |
0 |
0 |
Total Buy Value |
$0 |
$0 |
$0 |
$0 |
Total People Bought |
0 |
0 |
0 |
0 |
Total Buy Transactions |
0 |
0 |
0 |
0 |
Total Shares Sold |
0 |
0 |
0 |
12,646 |
Total Sell Value |
$0 |
$0 |
$0 |
$28,031 |
Total People Sold |
0 |
0 |
0 |
1 |
Total Sell Transactions |
0 |
0 |
0 |
4 |
End Date |
2024-02-29 |
2023-11-28 |
2023-05-30 |
2022-05-30 |
|
Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
3m +/- |
|
|
Form |
Nagao Hideki |
Director |
|
2022-11-28 |
4 |
S |
$2.25 |
$15,197 |
D/D |
(6,754) |
0 |
|
16% |
|
Nagao Hideki |
Director |
|
2022-11-22 |
4 |
S |
$2.13 |
$464 |
D/D |
(218) |
6,754 |
|
1% |
|
Nagao Hideki |
Director |
|
2022-11-21 |
4 |
S |
$2.18 |
$11,696 |
D/D |
(5,365) |
6,972 |
|
1% |
|
Nagao Hideki |
Director |
|
2022-11-17 |
4 |
S |
$2.18 |
$674 |
D/D |
(309) |
12,337 |
|
1% |
|
Matsuda Kazuko |
Chief Medical Officer |
|
2021-08-23 |
4 |
OE |
$2.30 |
$138,000 |
D/D |
60,000 |
322,996 |
|
- |
|
Iwaki Yuichi |
President and CEO |
|
2021-07-09 |
4 |
OE |
$2.54 |
$100,541 |
D/D |
39,583 |
966,933 |
|
- |
|
Matsuda Kazuko |
Chief Medical Officer |
|
2021-06-24 |
4 |
OE |
$2.46 |
$256,622 |
D/D |
102,804 |
262,996 |
|
- |
|
Obrien Geoffrey |
Vice President |
|
2021-05-19 |
4 |
OE |
$2.46 |
$109,122 |
D/D |
43,318 |
48,318 |
|
- |
|
Nagao Hideki |
Director |
|
2021-03-11 |
4 |
S |
$7.40 |
$17,420 |
D/D |
(2,354) |
12,646 |
|
43% |
|
Iwaki Yuichi |
President and CEO |
|
2021-02-25 |
4 |
OE |
$2.46 |
$212,175 |
D/D |
86,250 |
927,350 |
|
- |
|
3d Opportunity Master Fund |
10% Owner |
|
2021-01-11 |
3 |
IO |
$0.00 |
$0 |
I/I |
0 |
5,502,047 |
|
-25% |
|
Nagao Hideki |
Director |
|
2020-09-15 |
4 |
S |
$5.78 |
$5,780 |
D/D |
(1,000) |
15,000 |
|
-3% |
|
Nagao Hideki |
Director |
|
2020-08-06 |
4 |
OE |
$2.58 |
$38,700 |
D/D |
15,000 |
16,000 |
|
- |
|
Matsuda Kazuko |
Chief Medical Officer |
|
2020-06-12 |
4 |
OE |
$5.13 |
$102,600 |
D/D |
20,000 |
160,192 |
|
- |
|
Matsuda Kazuko |
Chief Medical Officer |
|
2020-04-08 |
4 |
OE |
$2.54 |
$72,253 |
D/D |
28,446 |
140,192 |
|
- |
|
Iwaki Yuichi |
President and CEO |
|
2020-04-08 |
4 |
OE |
$2.54 |
$153,459 |
D/D |
60,417 |
841,100 |
|
- |
|
Matsuda Kazuko |
Chief Medical Officer |
|
2020-03-13 |
4/A |
B |
$3.62 |
$7,240 |
D/D |
2,000 |
111,746 |
2.81 |
- |
|
Matsuda Kazuko |
Chief Medical Officer |
|
2020-03-13 |
4 |
B |
$3.62 |
$7,240 |
D/D |
2,000 |
111,476 |
2.81 |
43% |
|
Iwaki Yuichi |
President and CEO |
|
2020-03-12 |
4 |
B |
$3.10 |
$62,000 |
D/D |
20,000 |
780,683 |
2.81 |
85% |
|
Matsuda Kazuko |
Chief Medical Officer |
|
2019-06-12 |
4 |
OE |
$4.80 |
$177,600 |
D/D |
37,000 |
109,457 |
|
- |
|
Nagao Hideki |
Director |
|
2019-05-13 |
4 |
OE |
$2.77 |
$2,770 |
D/D |
1,000 |
1,000 |
|
- |
|
Okajima Masatsune |
VP and Head of Japanese Office |
|
2019-02-28 |
4 |
OE |
$2.46 |
$3,718,763 |
D/D |
886,950 |
1,040,530 |
|
- |
|
Okajima Masatsune |
VP and Head of Japanese Office |
|
2019-01-09 |
4 |
OE |
$2.20 |
$90,750 |
D/D |
41,250 |
153,580 |
|
- |
|
Iwaki Yuichi |
President and CEO |
|
2019-01-03 |
4 |
OE |
$2.20 |
$40,858 |
D/D |
18,572 |
759,392 |
|
- |
|
Iwaki Yuichi |
President and CEO |
|
2018-03-05 |
4 |
OE |
$2.20 |
$110,007 |
D/D |
50,003 |
740,594 |
|
- |
|
89 Records found
|
|
Page 1 of 4 |
|
|